Feb 13, 2007 by Brian LawlerQLT Pays UpQLT finally settles a patent infringement lawsuit over one of its top products.
Feb 13, 2007 by Brian LawlerRock-Solid News From OnyxResults show that the drug Nexavar works in another type of cancer.
Feb 13, 2007 by Brian LawlerCVT, We Wait for TheeCV Therapeutics' angina treatment could be set for a big boost.
Feb 12, 2007 by Brian LawlerHere Comes the Boom for InterMuneInterMune announced fourth-quarter results last week and updated investors on development timelines for its drug candidates.
Feb 12, 2007 by Brian LawlerI Love Drug StocksThis Valentine's Day, leave a special place in your heart for drug stocks.
Feb 9, 2007 by Brian LawlerSanofi's Loss Is Generic Drugmakers' GainSanofi-Aventis' loss in its patent infringement case against Teva and Amphastar is good news for Momenta.
Feb 9, 2007 by Brian LawlerPicking Up the Pace at Seattle GeneticsThe cash situation shows the shares of this drug development company could be appealing.
Feb 7, 2007 by Brian LawlerMylan Adjusts to the MatrixThe drugmaker got a bump from a new generic and settles in with its Matrix acquisition.
Feb 6, 2007 by Brian LawlerCelgene Mints the Green StuffBiotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance.
Feb 6, 2007 by Brian LawlerVertex Zooms OnVertex Pharmaceuticals announces its 2006 earnings numbers and guides investors for what to expect in the coming year.
Feb 5, 2007 by Brian LawlerGilead's Gold MineIn the fourth quarter, Gilead continues to rake in the cash from its top products.
Jan 31, 2007 by Brian LawlerExelixis Sticks With the PlanThe pharma keeps with the plan to bring at least three new drugs into the clinic each year.
Jan 31, 2007 by Brian LawlerNo Sickness for AmylinSales of the drugmaker's type-2 diabetes drugs showed solid growth.
Jan 31, 2007 by Brian LawlerNovo Nordisk Knows Sales GrowthDiabetes care leads the way for this Danish drugmaker.
Jan 31, 2007 by Brian LawlerMerck Plays the Waiting GameNew acquisitions may help the drugmaker weather tough times.
Jan 31, 2007 by Brian LawlerWarner Chilcott's Healthy GuidanceThe company may be new to the public markets, but it's far from a risky proposition.
Jan 31, 2007 by Brian LawlerNo Snoozing for SepracorThe company sees troubling sales trends with a key product.
Jan 31, 2007 by Brian LawlerYou're Only Hurting Yourself, ThailandThailand's decision to allow generics could do more harm than good.
Jan 31, 2007 by Brian LawlerNo Earnings Face-Lift Needed For AllerganThe company has made many investors rich, and it's not stopping now.
